Amgen Inc patent expiration

1. Corlanor patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 7 months from now)

US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 7 months from now)

US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 7 months from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7361649

(Pediatric)

AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Aug, 2026

(2 years from now)

US7361650

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Aug, 2026

(2 years from now)

US7879842

(Pediatric)

AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Aug, 2026

(2 years from now)

US7867996

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Jun, 2027

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 15, 2020
Pediatric Exclusivity(PED) Oct 15, 2020

Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient

NCE-1 date: 16 October, 2019

Market Authorisation Date: 15 April, 2015

Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride

Dosage: TABLET

How can I launch a generic of CORLANOR before it's drug patent expiration?
More Information on Dosage

CORLANOR family patents

Family Patents

2. Corlanor patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 7 months from now)

US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 7 months from now)

US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 7 months from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(2 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 15, 2020
New Product(NP) Apr 22, 2022
Orphan Drug Exclusivity(ODE-234) Apr 22, 2026
Pediatric Exclusivity(PED) Oct 22, 2026

Drugs and Companies using IVABRADINE ingredient

NCE-1 date: 22 October, 2025

Market Authorisation Date: 22 April, 2019

Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride

Dosage: SOLUTION

More Information on Dosage

CORLANOR family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Lumakras patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10519146 AMGEN INC KRAS G12C inhibitors and methods of using the same
May, 2038

(13 years from now)

US11827635 AMGEN INC Solid state forms
May, 2040

(15 years from now)

US11236091 AMGEN INC Solid state forms
May, 2040

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426404 AMGEN INC Dosing of KRAS inhibitor for treatment of cancers
Sep, 2040

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2026
Orphan Drug Exclusivity(ODE-352) May 28, 2028

Drugs and Companies using SOTORASIB ingredient

NCE-1 date: 28 May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...

Dosage: TABLET

More Information on Dosage

LUMAKRAS family patents

Family Patents

4. Otezla patent expiration

OTEZLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6020358 AMGEN INC Substituted phenethylsulfones and method of reducing TNFα levels
Oct, 2018

(5 years ago)

US7893101 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
Dec, 2023

(7 months ago)

US7427638 AMGEN INC (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof
Feb, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455536 AMGEN INC Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
Mar, 2023

(1 year, 3 months ago)

US8802717 AMGEN INC Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
Mar, 2023

(1 year, 3 months ago)

US7208516 AMGEN INC Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
Mar, 2023

(1 year, 3 months ago)

US7659302 AMGEN INC Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
Mar, 2023

(1 year, 3 months ago)

US9018243 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
Mar, 2023

(1 year, 3 months ago)

US6962940 AMGEN INC (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
Mar, 2023

(1 year, 3 months ago)

US9724330 AMGEN INC Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
Mar, 2023

(1 year, 3 months ago)

US7427638

(Pediatric)

AMGEN INC (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof
Aug, 2028

(4 years from now)

US10092541 AMGEN INC Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
May, 2034

(9 years from now)

US9872854 AMGEN INC Methods for the treatment of psoriatic arthritis using apremilast
May, 2034

(9 years from now)

US9872854

(Pediatric)

AMGEN INC Methods for the treatment of psoriatic arthritis using apremilast
Nov, 2034

(10 years from now)

US10092541

(Pediatric)

AMGEN INC Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
Nov, 2034

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-694) Sep 23, 2017
New Chemical Entity Exclusivity(NCE) Mar 21, 2019
New Indication(I-803) Jul 19, 2022
M(M-257) Apr 10, 2023
New Indication(I-884) Dec 20, 2024
Orphan Drug Exclusivity(ODE-248) Jul 19, 2026
M(M-299) Jul 20, 2026
Pediatric Exclusivity(PED) Jan 20, 2027
New Patient Population(NPP) Apr 25, 2027

Drugs and Companies using APREMILAST ingredient

NCE-1 date: 20 January, 2026

Market Authorisation Date: 21 March, 2014

Treatment: Treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriatic arthritis; Treatment of adult patients wi...

Dosage: TABLET

How can I launch a generic of OTEZLA before it's drug patent expiration?
More Information on Dosage

OTEZLA family patents

Family Patents